Induction of proapoptotic antibodies to triple-negative breast cancer by vaccination with TRAIL death receptor DR5 DNA

Marie P. Piechocki, Gen Sheng Wu, Richard F. Jones, Jennifer B. Jacob, Heather Gibson, Stephen P. Ethier, Judith Abrams, Hideo Yagita, K. Venuprasad, Wei Zen Wei

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

TNF-related apoptosis-inducing ligand receptor 2 [TRAIL-R2 or death receptor 5 (DR5)] is expressed at elevated levels in a broad range of solid tumors to mediate apoptotic signals from TRAIL or agonist antibodies. We tested the hypothesis that DR5 DNA vaccination will induce proapoptotic antibody to trigger apoptosis of tumor cells. BALB/c mice were electrovaccinated with DNA-encoding wild-type human DR5 (phDR5) or its derivatives. Resulting immune serum or purified immune IgG induced apoptosis in triple-negative breast cancer (TNBC) cells, which were also TRAIL sensitive. The proapoptotic activity of immune serum at dilutions of 0.5-2% was comparable to that of 1-2 μg/ml of TRAIL. Apoptotic activity of immune serum was enhanced by antibody crosslinking. Apoptotic cell death induced by anti-DR5 antibody was shown by the cleavage of PARP and caspase-3. In contrast, immune serum had no effect on the proliferation of activated human T cells, which expressed low levels of DR5. In vivo, hDR5 reactive immune serum prevented growth of SUM159 TNBC cells in severe combined immune-deficient mice. DR5-specific IFN-γ-secreting T cells were also induced by DNA vaccination. Furthermore, the feasibility to overcome immune tolerance to self DR5 was shown by the induction of mouse DR5-binding antibody after electrovaccination of BALB/c mice with pmDR5ectm-Td1 encoding a fusion protein of mouse DR5 and an immunogenic fragment of tetanus toxin. These findings support DR5 as a promising vaccine target for controlling TNBC and other DR5-positive cancers.

Original languageEnglish (US)
Pages (from-to)2562-2572
Number of pages11
JournalInternational Journal of Cancer
Volume131
Issue number11
DOIs
StatePublished - Dec 1 2012
Externally publishedYes

Fingerprint

Triple Negative Breast Neoplasms
TNF-Related Apoptosis-Inducing Ligand Receptors
Death Domain Receptors
Vaccination
Antibodies
DNA
Immune Sera
Apoptosis
Tetanus Toxin
T-Lymphocytes
Neoplasms
Immune Tolerance
Caspase 3
Cell Death
Vaccines

Keywords

  • antibody
  • apoptosis
  • DNA vaccine
  • DR5 (TRAIL-R2)
  • triple-negative breast cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Piechocki, M. P., Wu, G. S., Jones, R. F., Jacob, J. B., Gibson, H., Ethier, S. P., ... Wei, W. Z. (2012). Induction of proapoptotic antibodies to triple-negative breast cancer by vaccination with TRAIL death receptor DR5 DNA. International Journal of Cancer, 131(11), 2562-2572. https://doi.org/10.1002/ijc.27534

Induction of proapoptotic antibodies to triple-negative breast cancer by vaccination with TRAIL death receptor DR5 DNA. / Piechocki, Marie P.; Wu, Gen Sheng; Jones, Richard F.; Jacob, Jennifer B.; Gibson, Heather; Ethier, Stephen P.; Abrams, Judith; Yagita, Hideo; Venuprasad, K.; Wei, Wei Zen.

In: International Journal of Cancer, Vol. 131, No. 11, 01.12.2012, p. 2562-2572.

Research output: Contribution to journalArticle

Piechocki, MP, Wu, GS, Jones, RF, Jacob, JB, Gibson, H, Ethier, SP, Abrams, J, Yagita, H, Venuprasad, K & Wei, WZ 2012, 'Induction of proapoptotic antibodies to triple-negative breast cancer by vaccination with TRAIL death receptor DR5 DNA', International Journal of Cancer, vol. 131, no. 11, pp. 2562-2572. https://doi.org/10.1002/ijc.27534
Piechocki, Marie P. ; Wu, Gen Sheng ; Jones, Richard F. ; Jacob, Jennifer B. ; Gibson, Heather ; Ethier, Stephen P. ; Abrams, Judith ; Yagita, Hideo ; Venuprasad, K. ; Wei, Wei Zen. / Induction of proapoptotic antibodies to triple-negative breast cancer by vaccination with TRAIL death receptor DR5 DNA. In: International Journal of Cancer. 2012 ; Vol. 131, No. 11. pp. 2562-2572.
@article{9d3a6532c916459c9512e943f47aea4e,
title = "Induction of proapoptotic antibodies to triple-negative breast cancer by vaccination with TRAIL death receptor DR5 DNA",
abstract = "TNF-related apoptosis-inducing ligand receptor 2 [TRAIL-R2 or death receptor 5 (DR5)] is expressed at elevated levels in a broad range of solid tumors to mediate apoptotic signals from TRAIL or agonist antibodies. We tested the hypothesis that DR5 DNA vaccination will induce proapoptotic antibody to trigger apoptosis of tumor cells. BALB/c mice were electrovaccinated with DNA-encoding wild-type human DR5 (phDR5) or its derivatives. Resulting immune serum or purified immune IgG induced apoptosis in triple-negative breast cancer (TNBC) cells, which were also TRAIL sensitive. The proapoptotic activity of immune serum at dilutions of 0.5-2{\%} was comparable to that of 1-2 μg/ml of TRAIL. Apoptotic activity of immune serum was enhanced by antibody crosslinking. Apoptotic cell death induced by anti-DR5 antibody was shown by the cleavage of PARP and caspase-3. In contrast, immune serum had no effect on the proliferation of activated human T cells, which expressed low levels of DR5. In vivo, hDR5 reactive immune serum prevented growth of SUM159 TNBC cells in severe combined immune-deficient mice. DR5-specific IFN-γ-secreting T cells were also induced by DNA vaccination. Furthermore, the feasibility to overcome immune tolerance to self DR5 was shown by the induction of mouse DR5-binding antibody after electrovaccination of BALB/c mice with pmDR5ectm-Td1 encoding a fusion protein of mouse DR5 and an immunogenic fragment of tetanus toxin. These findings support DR5 as a promising vaccine target for controlling TNBC and other DR5-positive cancers.",
keywords = "antibody, apoptosis, DNA vaccine, DR5 (TRAIL-R2), triple-negative breast cancer",
author = "Piechocki, {Marie P.} and Wu, {Gen Sheng} and Jones, {Richard F.} and Jacob, {Jennifer B.} and Heather Gibson and Ethier, {Stephen P.} and Judith Abrams and Hideo Yagita and K. Venuprasad and Wei, {Wei Zen}",
year = "2012",
month = "12",
day = "1",
doi = "10.1002/ijc.27534",
language = "English (US)",
volume = "131",
pages = "2562--2572",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "11",

}

TY - JOUR

T1 - Induction of proapoptotic antibodies to triple-negative breast cancer by vaccination with TRAIL death receptor DR5 DNA

AU - Piechocki, Marie P.

AU - Wu, Gen Sheng

AU - Jones, Richard F.

AU - Jacob, Jennifer B.

AU - Gibson, Heather

AU - Ethier, Stephen P.

AU - Abrams, Judith

AU - Yagita, Hideo

AU - Venuprasad, K.

AU - Wei, Wei Zen

PY - 2012/12/1

Y1 - 2012/12/1

N2 - TNF-related apoptosis-inducing ligand receptor 2 [TRAIL-R2 or death receptor 5 (DR5)] is expressed at elevated levels in a broad range of solid tumors to mediate apoptotic signals from TRAIL or agonist antibodies. We tested the hypothesis that DR5 DNA vaccination will induce proapoptotic antibody to trigger apoptosis of tumor cells. BALB/c mice were electrovaccinated with DNA-encoding wild-type human DR5 (phDR5) or its derivatives. Resulting immune serum or purified immune IgG induced apoptosis in triple-negative breast cancer (TNBC) cells, which were also TRAIL sensitive. The proapoptotic activity of immune serum at dilutions of 0.5-2% was comparable to that of 1-2 μg/ml of TRAIL. Apoptotic activity of immune serum was enhanced by antibody crosslinking. Apoptotic cell death induced by anti-DR5 antibody was shown by the cleavage of PARP and caspase-3. In contrast, immune serum had no effect on the proliferation of activated human T cells, which expressed low levels of DR5. In vivo, hDR5 reactive immune serum prevented growth of SUM159 TNBC cells in severe combined immune-deficient mice. DR5-specific IFN-γ-secreting T cells were also induced by DNA vaccination. Furthermore, the feasibility to overcome immune tolerance to self DR5 was shown by the induction of mouse DR5-binding antibody after electrovaccination of BALB/c mice with pmDR5ectm-Td1 encoding a fusion protein of mouse DR5 and an immunogenic fragment of tetanus toxin. These findings support DR5 as a promising vaccine target for controlling TNBC and other DR5-positive cancers.

AB - TNF-related apoptosis-inducing ligand receptor 2 [TRAIL-R2 or death receptor 5 (DR5)] is expressed at elevated levels in a broad range of solid tumors to mediate apoptotic signals from TRAIL or agonist antibodies. We tested the hypothesis that DR5 DNA vaccination will induce proapoptotic antibody to trigger apoptosis of tumor cells. BALB/c mice were electrovaccinated with DNA-encoding wild-type human DR5 (phDR5) or its derivatives. Resulting immune serum or purified immune IgG induced apoptosis in triple-negative breast cancer (TNBC) cells, which were also TRAIL sensitive. The proapoptotic activity of immune serum at dilutions of 0.5-2% was comparable to that of 1-2 μg/ml of TRAIL. Apoptotic activity of immune serum was enhanced by antibody crosslinking. Apoptotic cell death induced by anti-DR5 antibody was shown by the cleavage of PARP and caspase-3. In contrast, immune serum had no effect on the proliferation of activated human T cells, which expressed low levels of DR5. In vivo, hDR5 reactive immune serum prevented growth of SUM159 TNBC cells in severe combined immune-deficient mice. DR5-specific IFN-γ-secreting T cells were also induced by DNA vaccination. Furthermore, the feasibility to overcome immune tolerance to self DR5 was shown by the induction of mouse DR5-binding antibody after electrovaccination of BALB/c mice with pmDR5ectm-Td1 encoding a fusion protein of mouse DR5 and an immunogenic fragment of tetanus toxin. These findings support DR5 as a promising vaccine target for controlling TNBC and other DR5-positive cancers.

KW - antibody

KW - apoptosis

KW - DNA vaccine

KW - DR5 (TRAIL-R2)

KW - triple-negative breast cancer

UR - http://www.scopus.com/inward/record.url?scp=84867034026&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867034026&partnerID=8YFLogxK

U2 - 10.1002/ijc.27534

DO - 10.1002/ijc.27534

M3 - Article

C2 - 22419388

AN - SCOPUS:84867034026

VL - 131

SP - 2562

EP - 2572

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 11

ER -